Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure (SERCA-LVAD)
The aim of the study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a), driven by the CMV promoter (AAV1-CMV-SERCA2a), to heart failure patients that have received a left ventricular assist device (LVAD) for an accepted clinical indication. It is a randomised, double-blind study of 24 patients that will be randomised to receive either the study drug (AAV1.SERCA2a) or placebo.
The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key factor in depression of contraction, and that restoration of SERCA2a levels can improve function to near normal levels. The vector will be delivered during a cardiac catheterisation procedure by a 10-minute infusion into the coronary arteries.
Myocardial tissue is obtained at the time of LVAD placement, as a routine part of device implantation. Further samples will be obtained when the heart is transplanted or the LVAD removed. Measures of tissue inflammation as well as efficacy of gene transfer will be made by comparing these two samples. Recovery of contractile function of the heart will be assessed during attempts to wean patients from the LVAD using standard protocols.
The results will be assessed in conjunction with two companion studies which will start earlier in the US, one performing SERCA2a gene transfer with the same vector, but delivered by direct injection into the myocardium during LVAD insertion, and one using AAV1-CMV-SERCA2a delivered percutaneously in heart failure patients. The latter has both a dose-ranging and placebo-controlled arm.
Chronic Heart Failure
Patients That Have Received a Left Ventricular Assist Device
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device|
- Overall safety and feasibility of administering AAV1/SERCA2a to LVAD patients. Overall safety and feasibility of administering AAV1/SERCA2a to LVAD patients [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Safety is defined as incidence of death and major adverse cardiovascular events, and out of range laboratory values. Both AAV1/SERCA2a treated cohorts (NAb+ and NAb-) will be compared to the placebo group.
- Presence of exogenous viral vector genome in the myocardium measured by qPCR for the viral DNA [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Left ventricular function assessed by echocardiography and exercise capacity (6MWT, MVO2)during minimal LVAD support (low/no flow settings depending upon device) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Levels of SERCA2a protein [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Other relevant proteins e.g. phospholamban, the sarcoplasmic reticulum calcium release channel, the Na+/Ca2+-exchanger. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Function of isolated myocytes [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||July 2014|
|Estimated Study Completion Date:||May 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Active Comparator: AAV1/SERCA2A
SERCA gene therapy
AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
Other Name: MYDICAR (R)
Placebo Comparator: Placebo
Placebo (saline solution)
Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00534703
|Contact: Sian Harding||020 7594 firstname.lastname@example.org|
|Contact: Alexander Lyon||020 7594 email@example.com|
|Papworth Hospital||Not yet recruiting|
|Cambridge, United Kingdom, CB23 3RE|
|Principal Investigator: Steven Tsui|
|Harefield Hospital, Royal Brompton and Harefiled NHS Trust||Recruiting|
|Middlesex, United Kingdom, UB9 6JH|
|Principal Investigator: Nick Banner|
|Principal Investigator:||Sian Harding||Imperial College London|
|Principal Investigator:||Alexandar Lyon||Imperial College London|